

## II. CLAIMS

1-9. Cancelled

10. (Withdrawn) A method according to claim 9, wherein the fibrin matrix is used in an angiogenesis test.

11-13. Cancelled

14. (Withdrawn) A pharmaceutical composition, comprising fibrinogen and a pharmaceutically acceptable carrier, wherein the fibrinogen consists of a selected fibrinogen variant or a fibrinogen enriched or depleted in a fibrinogen variant.

15. (Withdrawn) A pharmaceutical composition according to claim 14, wherein the fibrinogen consists of HMW fibrinogen or of a mixture of fibrinogen variants enriched in HMW fibrinogen or depleted in LMW en/of LMW' fibrinogen.

16. (Withdrawn) A pharmaceutical composition according to claim 15, which is suitable for promoting wound healing, inhibiting or preventing cicatrization or treating burns.

17. (Withdrawn) A pharmaceutical composition according to claim 14, wherein the fibrinogen consists of LMW fibrinogen or of a mixture of fibrinogen variants enriched in LMW fibrinogen or depleted in HMW fibrinogen.

18. (Withdrawn) A pharmaceutical composition according to claim 14, wherein the fibrinogen consists of LMW' fibrinogen or of a mixture of fibrinogen variants enriched in LMW' fibrinogen or depleted in HMW fibrinogen.

19. (Withdrawn) A pharmaceutical composition according to claim 17, which is suitable for inhibiting or preventing tumor growth or adhesions.

20. (Withdrawn) A test kit, comprising components for the formation of a fibrin matrix, including fibrinogen, wherein the fibrinogen consists of a selected fibrinogen variant or a fibrinogen enriched or depleted in a selected fibrinogen variant.

21. (Withdrawn) A test kit according to claim 20, wherein the fibrinogen consists of HMW fibrinogen or of a mixture of fibrinogen variants enriched in HMW fibrinogen or depleted in LMW and/or LMW' fibrinogen.

22. (Withdrawn) A test kit according to claim 20, also comprising an enzyme suitable for forming fibrin from fibrinogen, such as thrombin, and optionally factor XIIIa and/or  $\text{CaCl}_2$ .

23. (Withdrawn) A test kit according to claim 20, also comprising components for effecting angiogenesis.

24. (Withdrawn) A test kit according to claim 23, comprising as components for effecting angiogenesis one or more angiogenic growth factors, such as fibroblast growth factor-2 (FGF-2) or vascular endothelial growth factor (VEGF), and/or tumor necrosis factor alpha ( $\text{TNF-}\alpha$ ), and/or cells, such as human endothelial cells.

25-46. Cancelled

47. (New) A method for accelerating angiogenesis in a patient comprising topically administering to the patient at a site angiogenesis acceleration is desired of a fibrin matrix made by the process of forming a fibrin matrix from a composition comprising fibrinogen and a pharmaceutically acceptable carrier, wherein the fibrinogen has a high molecular weight (HMW) content of at least 80 % (w/w) of the total fibrinogen amount.

48. (New) The method of claim 47, where wherein the high molecular weight fibrinogen content is a mixture enriched in the Fib420 form of fibrinogen.

49. (New) The method of claim 47 where the fibrin matrix is applied to burnt tissue of a patient.

50. (New) The method of claim 47 where the fibrin matrix is applied to wounded tissue of a patient.

51. (New) The method of claim 47 where the fibrin matrix is applied to an internal organ of a patient during a surgical procedure.

52. (New) The method of claim 47, wherein the composition further contains one of more of factor XIIIa,  $\text{CaCl}_2$  or an enzyme capable of forming fibrin from fibrinogen.

53. (New) The method of claim 52, where the enzyme is thrombin.

54. (New) A method for decelerating angiogenesis in a patient comprising topically administering to the patient

at a site angiogenesis deceleration is desired, intravenous injection or infusion of a fibrin matrix made by the process of forming a fibrin matrix from a composition comprising fibrinogen and a pharmaceutically acceptable carrier, wherein the fibrinogen has a low molecular weight content (LMW) of at least 40 % (w/w) of the total fibrinogen amount, forming a fibrin matrix from said composition.

55. (New) The method of claim 54, where wherein the low molecular weight fibrinogen content is a mixture enriched in the gamma form of fibrinogen.

56. (New) The method of claim 54, wherein the composition further contains one of more of factor XIIIa,  $\text{CaCl}_2$  or an enzyme capable of forming fibrin from fibrinogen.

57. (New) The method of claim 56, where the enzyme is thrombin.

58. (New) The method for decelerating angiogenesis in a patient of claim 54 where the composition is topically administered.

59. (New) The method of claim 54 where the composition is topically administered to an internal organ of a patient during the course of a surgical procedure.

60. (New) The method of claim 58, wherein the composition further contains one of more of factor XIIIa,  $\text{CaCl}_2$  or enzyme capable of forming fibrin from fibrinogen.

61. (New) The method of claim 60, where the enzyme is thrombin.

62. (New) The method of claim 58 where the composition is applied to a wound of a patient to lessen scar formation or adhesions of the wound.

63. (New) The method for decelerating angiogenesis in a patient of claim 54 where the composition is administered intravenously.

64. (New) The method of claim 63, wherein the composition further contains one of more of factor XIIIa,  $\text{CaCl}_2$  or an enzyme capable of forming fibrin from fibrinogen.

65. (New) The method of claim 64, where the enzyme is thrombin.

66. (New) The method for decelerating angiogenesis in a patient of claim 54 where the composition is administered by infusion.

67. (New) The method of claim 66, wherein the composition further contains one of more of factor XIIIa,  $\text{CaCl}_2$  or enzyme capable of forming fibrin from fibrinogen.

68. (New) The method of claim 67 where the enzyme is thrombin.